Evidence map›Paper›PMID 41277088›Full record

ArticleChemistryOpen2026

Synthesis of Pyrido[2,3-d]Azolopyrimidinones: Design and Epidermal Growth Factor Receptor-Targeted Molecular Docking Toward Novel Anticancer Leads.

Sobhi M Gomha, Sami A Al-Hussain, Basant Farag, AbdElAziz A Nayl, Wesam Hussein, Abdelwahed R Sayed, Magdi E A Zaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sobhi M GomhaDepartment of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, Saudi Arabia.ORCID 0000-0002-7739-2837
Sami A Al-HussainDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Basant FaragDepartment of Chemistry, Faculty of Science, Zagazig University, Zagazig, Egypt.
AbdElAziz A NaylDepartment of Chemistry, College of Science, Jouf University, Sakaka, Saudi Arabia.
Wesam HusseinDepartment of Chemistry, Faculty of Science, Islamic University of Madinah, Madinah, Saudi Arabia.
Abdelwahed R SayedDepartment of Chemistry, Faculty of Science, University of Beni Suef, Beni Suef, Egypt.
Magdi E A ZakiDepartment of Chemistry, Faculty of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.ORCID 0000-0002-5643-9202

Funding

Imam Mohammad Ibn Saud Islamic University IMSIU-DDRSP2501
6 · The paper itself

Abstract

A new class of pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidinones and pyrido[2,3-d]thiazolo[3,2-a]pyrimidinones was synthesized by reacting 5-phenyl-2-thioxo-2,3-dihydropyrido[2,3-d]pyrimidin-4(1H)-one with hydrazonoyl halides and α-bromoketones via a Knoevenagel-cyclocondensation followed by heteroannulation. Structures were confirmed by elemental analysis and IR,

Indexed as

Antineoplastic AgentsDrug DesignErbB ReceptorsMolecular Docking SimulationProtein Kinase InhibitorsPyrimidinonesDrug Screening Assays, AntitumorHep G2 CellsHumansStructure-Activity RelationshipAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsPyrimidinonesADMETanticancer agentsEGFR inhibitorshydrazonoyl halidesmolecular dockingpyridopyrimidines

Identifiers

PMID41277088
PMCPMC13051936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.